CA2928665A1 - Crystalline forms of therapeutic compounds and uses thereof - Google Patents

Info

Publication number

CA2928665A1

CA2928665A1 CA2928665A CA2928665A CA2928665A1 CA 2928665 A1 CA2928665 A1 CA 2928665A1 CA 2928665 A CA2928665 A CA 2928665A CA 2928665 A CA2928665 A CA 2928665A CA 2928665 A1 CA2928665 A1 CA 2928665A1

Authority

CA

Canada

Prior art keywords

less

equal

crystalline form

pharmaceutical composition

compound

Prior art date

2013-11-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 51
• 230000001225 therapeutic effect Effects 0.000 title description 20
• 239000002245 particle Substances 0.000 claims abstract description 396
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 176
• 238000000034 method Methods 0.000 claims abstract description 148
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 89
• 201000010099 disease Diseases 0.000 claims abstract description 75
• 239000002105 nanoparticle Substances 0.000 claims abstract description 17
• 239000000203 mixture Substances 0.000 claims description 247
• 239000003795 chemical substances by application Substances 0.000 claims description 125
• 238000000576 coating method Methods 0.000 claims description 97
• 239000011248 coating agent Substances 0.000 claims description 88
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 61
• 239000000725 suspension Substances 0.000 claims description 49
• 206010028980 Neoplasm Diseases 0.000 claims description 46
• 230000008569 process Effects 0.000 claims description 44
• 208000002780 macular degeneration Diseases 0.000 claims description 36
• 208000022873 Ocular disease Diseases 0.000 claims description 30
• 239000003102 growth factor Substances 0.000 claims description 29
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
• 230000011664 signaling Effects 0.000 claims description 25
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 24
• 239000007771 core particle Substances 0.000 claims description 19
• 201000011510 cancer Diseases 0.000 claims description 16
• 238000002347 injection Methods 0.000 claims description 16
• 239000007924 injection Substances 0.000 claims description 16
• 230000002209 hydrophobic effect Effects 0.000 claims description 14
• 230000002401 inhibitory effect Effects 0.000 claims description 14
• 230000002062 proliferating effect Effects 0.000 claims description 13
• 229920000428 triblock copolymer Polymers 0.000 claims description 13
• 239000003937 drug carrier Substances 0.000 claims description 10
• 238000011200 topical administration Methods 0.000 claims description 10
• 238000004519 manufacturing process Methods 0.000 claims description 9
• 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 7
• 201000011190 diabetic macular edema Diseases 0.000 claims description 7
• 208000017442 Retinal disease Diseases 0.000 claims description 6
• 206010038923 Retinopathy Diseases 0.000 claims description 6
• 238000001238 wet grinding Methods 0.000 claims description 6
• 238000000338 in vitro Methods 0.000 claims description 4
• 239000002736 nonionic surfactant Substances 0.000 claims description 4
• 208000004644 retinal vein occlusion Diseases 0.000 claims description 4
• 239000002002 slurry Substances 0.000 claims description 3
• 238000003756 stirring Methods 0.000 claims description 3
• 206010055665 Corneal neovascularisation Diseases 0.000 claims description 2
• 201000000159 corneal neovascularization Diseases 0.000 claims description 2
• TWCHPQYRRRXRDD-UHFFFAOYSA-N 4-[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinazolin-7-yl]oxy-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCC(=O)N(CC1)CCC21COC2 TWCHPQYRRRXRDD-UHFFFAOYSA-N 0.000 claims 6
• 229940125898 compound 5 Drugs 0.000 abstract description 199
• 210000003097 mucus Anatomy 0.000 abstract description 69
• 230000000149 penetrating effect Effects 0.000 abstract description 17
• -1 collagcnases Proteins 0.000 description 194
• 239000011162 core material Substances 0.000 description 132
• 238000009472 formulation Methods 0.000 description 115
• 239000008177 pharmaceutical agent Substances 0.000 description 99
• 239000002904 solvent Substances 0.000 description 76
• 239000000463 material Substances 0.000 description 66
• 210000001519 tissue Anatomy 0.000 description 60
• 229920000642 polymer Polymers 0.000 description 56
• 210000001508 eye Anatomy 0.000 description 44
• 239000003814 drug Substances 0.000 description 39
• 239000004480 active ingredient Substances 0.000 description 38
• 210000004027 cell Anatomy 0.000 description 37
• 238000003801 milling Methods 0.000 description 37
• 239000000243 solution Substances 0.000 description 36
• 230000033115 angiogenesis Effects 0.000 description 35
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
• 239000002086 nanomaterial Substances 0.000 description 29
• 239000000546 pharmaceutical excipient Substances 0.000 description 27
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 26
• 235000002639 sodium chloride Nutrition 0.000 description 26
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 25
• 229940079593 drug Drugs 0.000 description 25
• 229920001223 polyethylene glycol Polymers 0.000 description 25
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 24
• 239000002738 chelating agent Substances 0.000 description 24
• 230000001965 increasing effect Effects 0.000 description 22
• 238000001556 precipitation Methods 0.000 description 22
• 239000003755 preservative agent Substances 0.000 description 21
• 208000027866 inflammatory disease Diseases 0.000 description 20
• 239000000843 powder Substances 0.000 description 20
• 150000003839 salts Chemical class 0.000 description 20
• 206010013774 Dry eye Diseases 0.000 description 19
• 230000001594 aberrant effect Effects 0.000 description 19
• 230000002159 abnormal effect Effects 0.000 description 19
• 230000004682 mucosal barrier function Effects 0.000 description 19
• 229920000136 polysorbate Polymers 0.000 description 19
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 18
• 235000019441 ethanol Nutrition 0.000 description 18
• 239000012530 fluid Substances 0.000 description 18
• 229920002451 polyvinyl alcohol Polymers 0.000 description 18
• 239000003381 stabilizer Substances 0.000 description 18
• 239000000126 substance Substances 0.000 description 18
• 238000002560 therapeutic procedure Methods 0.000 description 18
• 238000011282 treatment Methods 0.000 description 18
• 238000004945 emulsification Methods 0.000 description 17
• 239000013078 crystal Substances 0.000 description 16
• 239000003380 propellant Substances 0.000 description 16
• 239000004094 surface-active agent Substances 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
• 238000003113 dilution method Methods 0.000 description 15
• 239000002159 nanocrystal Substances 0.000 description 15
• 239000003921 oil Substances 0.000 description 15
• 235000018102 proteins Nutrition 0.000 description 15
• 108090000623 proteins and genes Proteins 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• 210000001525 retina Anatomy 0.000 description 15
• 239000007787 solid Substances 0.000 description 15
• 239000012929 tonicity agent Substances 0.000 description 15
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 14
• 208000023275 Autoimmune disease Diseases 0.000 description 14
• 206010046851 Uveitis Diseases 0.000 description 14
• 239000007788 liquid Substances 0.000 description 14
• 201000004569 Blindness Diseases 0.000 description 13
• 206010012689 Diabetic retinopathy Diseases 0.000 description 13
• 206010061218 Inflammation Diseases 0.000 description 13
• 229920002472 Starch Polymers 0.000 description 13
• 239000004599 antimicrobial Substances 0.000 description 13
• 208000035475 disorder Diseases 0.000 description 13
• 230000004054 inflammatory process Effects 0.000 description 13
• 230000005855 radiation Effects 0.000 description 13
• 235000019698 starch Nutrition 0.000 description 13
• 208000024891 symptom Diseases 0.000 description 13
• 210000001138 tear Anatomy 0.000 description 13
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 12
• 239000000969 carrier Substances 0.000 description 12
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
• 239000003085 diluting agent Substances 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• 208000010412 Glaucoma Diseases 0.000 description 11
• 208000001344 Macular Edema Diseases 0.000 description 11
• 229920001577 copolymer Polymers 0.000 description 11
• 239000000839 emulsion Substances 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 229940043355 kinase inhibitor Drugs 0.000 description 11
• 239000013642 negative control Substances 0.000 description 11
• 235000019198 oils Nutrition 0.000 description 11
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 11
• 229920001983 poloxamer Polymers 0.000 description 11
• 229940032147 starch Drugs 0.000 description 11
• 239000008107 starch Substances 0.000 description 11
• 230000001954 sterilising effect Effects 0.000 description 11
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 10
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 230000006378 damage Effects 0.000 description 10
• 229960004756 ethanol Drugs 0.000 description 10
• 239000004615 ingredient Substances 0.000 description 10
• 239000003112 inhibitor Substances 0.000 description 10
• 239000011343 solid material Substances 0.000 description 10
• 238000004659 sterilization and disinfection Methods 0.000 description 10
• 208000011594 Autoinflammatory disease Diseases 0.000 description 9
• 239000002671 adjuvant Substances 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 210000004204 blood vessel Anatomy 0.000 description 9
• 230000004438 eyesight Effects 0.000 description 9
• 238000005259 measurement Methods 0.000 description 9
• 229920002635 polyurethane Polymers 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 8
• 206010060999 Benign neoplasm Diseases 0.000 description 8
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
• 206010058202 Cystoid macular oedema Diseases 0.000 description 8
• 206010025421 Macule Diseases 0.000 description 8
• 239000004793 Polystyrene Substances 0.000 description 8
• 239000000443 aerosol Substances 0.000 description 8
• 239000006172 buffering agent Substances 0.000 description 8
• 239000001768 carboxy methyl cellulose Substances 0.000 description 8
• 201000010206 cystoid macular edema Diseases 0.000 description 8
• 239000006196 drop Substances 0.000 description 8
• 238000005538 encapsulation Methods 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 239000008101 lactose Substances 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 210000004379 membrane Anatomy 0.000 description 8
• 239000012528 membrane Substances 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 230000000069 prophylactic effect Effects 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 239000001993 wax Substances 0.000 description 8
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
• 239000002202 Polyethylene glycol Substances 0.000 description 7
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
• 229920002125 Sokalan® Polymers 0.000 description 7
• 229930006000 Sucrose Natural products 0.000 description 7
• 230000002776 aggregation Effects 0.000 description 7
• 235000010443 alginic acid Nutrition 0.000 description 7
• 229920000615 alginic acid Polymers 0.000 description 7
• ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 7
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 7
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 7
• 229940105329 carboxymethylcellulose Drugs 0.000 description 7
• 229920002678 cellulose Polymers 0.000 description 7
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
• 235000014113 dietary fatty acids Nutrition 0.000 description 7
• 239000002552 dosage form Substances 0.000 description 7
• 229930195729 fatty acid Natural products 0.000 description 7
• 239000000194 fatty acid Substances 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 238000000227 grinding Methods 0.000 description 7
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 7
• 239000010410 layer Substances 0.000 description 7
• 239000002674 ointment Substances 0.000 description 7
• 229920000747 poly(lactic acid) Polymers 0.000 description 7
• 229920000056 polyoxyethylene ether Polymers 0.000 description 7
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
• 229920000053 polysorbate 80 Polymers 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 7
• 239000005720 sucrose Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
• 238000004220 aggregation Methods 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 229960000686 benzalkonium chloride Drugs 0.000 description 6
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 6
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
• 239000012472 biological sample Substances 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 210000003161 choroid Anatomy 0.000 description 6
• 238000002425 crystallisation Methods 0.000 description 6
• 230000008025 crystallization Effects 0.000 description 6
• 238000002296 dynamic light scattering Methods 0.000 description 6
• 239000003995 emulsifying agent Substances 0.000 description 6
• 210000001035 gastrointestinal tract Anatomy 0.000 description 6
• 238000001415 gene therapy Methods 0.000 description 6
• 150000004677 hydrates Chemical class 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 235000010445 lecithin Nutrition 0.000 description 6
• 239000000787 lecithin Substances 0.000 description 6
• 229940067606 lecithin Drugs 0.000 description 6
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 229920001432 poly(L-lactide) Polymers 0.000 description 6
• 239000004417 polycarbonate Substances 0.000 description 6
• 229940051841 polyoxyethylene ether Drugs 0.000 description 6
• 229940068965 polysorbates Drugs 0.000 description 6
• 229920002223 polystyrene Polymers 0.000 description 6
• 239000004814 polyurethane Substances 0.000 description 6
• 230000002335 preservative effect Effects 0.000 description 6
• 230000002035 prolonged effect Effects 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• 239000000829 suppository Substances 0.000 description 6
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
• 206010030113 Oedema Diseases 0.000 description 5
• 239000005642 Oleic acid Substances 0.000 description 5
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
• 239000004698 Polyethylene Substances 0.000 description 5
• 229920000954 Polyglycolide Polymers 0.000 description 5
• 229920001213 Polysorbate 20 Polymers 0.000 description 5
• 108091008605 VEGF receptors Proteins 0.000 description 5
• 239000000783 alginic acid Substances 0.000 description 5
• 229960001126 alginic acid Drugs 0.000 description 5
• 150000004781 alginic acids Chemical class 0.000 description 5
• 239000004037 angiogenesis inhibitor Substances 0.000 description 5
• 239000003963 antioxidant agent Substances 0.000 description 5
• 235000006708 antioxidants Nutrition 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 208000010217 blepharitis Diseases 0.000 description 5
• 229960003655 bromfenac Drugs 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 235000010980 cellulose Nutrition 0.000 description 5
• 235000012343 cottonseed oil Nutrition 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 230000002500 effect on skin Effects 0.000 description 5
• 235000011187 glycerol Nutrition 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 239000003701 inert diluent Substances 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 238000007918 intramuscular administration Methods 0.000 description 5
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
• 239000000314 lubricant Substances 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 208000030159 metabolic disease Diseases 0.000 description 5
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
• 230000003232 mucoadhesive effect Effects 0.000 description 5
• 239000004006 olive oil Substances 0.000 description 5
• 239000003960 organic solvent Substances 0.000 description 5
• 230000035515 penetration Effects 0.000 description 5
• 229940124531 pharmaceutical excipient Drugs 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 239000007909 solid dosage form Substances 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 229950000578 vatalanib Drugs 0.000 description 5
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 5
• 230000004393 visual impairment Effects 0.000 description 5
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 4
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 4
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 4
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
• 229920001817 Agar Polymers 0.000 description 4
• XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 229920002261 Corn starch Polymers 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
• JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 4
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 4
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 206010027476 Metastases Diseases 0.000 description 4
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
• 208000028389 Nerve injury Diseases 0.000 description 4
• 229920005689 PLLA-PGA Polymers 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
• 229920001244 Poly(D,L-lactide) Polymers 0.000 description 4
• 239000004952 Polyamide Substances 0.000 description 4
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 201000000582 Retinoblastoma Diseases 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 108010081667 aflibercept Proteins 0.000 description 4
• 239000008272 agar Substances 0.000 description 4
• 229940023476 agar Drugs 0.000 description 4
• 235000010419 agar Nutrition 0.000 description 4
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000012296 anti-solvent Substances 0.000 description 4
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 229920001400 block copolymer Polymers 0.000 description 4
• 238000009835 boiling Methods 0.000 description 4
• 235000010216 calcium carbonate Nutrition 0.000 description 4
• 229910000019 calcium carbonate Inorganic materials 0.000 description 4
• 229960003563 calcium carbonate Drugs 0.000 description 4
• 230000015556 catabolic process Effects 0.000 description 4
• 229960002412 cediranib Drugs 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 229960000541 cetyl alcohol Drugs 0.000 description 4
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 229960004106 citric acid Drugs 0.000 description 4
• 235000015165 citric acid Nutrition 0.000 description 4
• 235000019868 cocoa butter Nutrition 0.000 description 4
• 229940110456 cocoa butter Drugs 0.000 description 4
• 239000002285 corn oil Substances 0.000 description 4
• 235000005687 corn oil Nutrition 0.000 description 4
• 239000008120 corn starch Substances 0.000 description 4
• 229940099112 cornstarch Drugs 0.000 description 4
• 239000002385 cottonseed oil Substances 0.000 description 4
• 230000001186 cumulative effect Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000006073 displacement reaction Methods 0.000 description 4
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 4
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 4
• 229940093471 ethyl oleate Drugs 0.000 description 4
• 239000005038 ethylene vinyl acetate Substances 0.000 description 4
• 239000003889 eye drop Substances 0.000 description 4
• 210000000744 eyelid Anatomy 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• 239000000796 flavoring agent Substances 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 239000008103 glucose Substances 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 229910021645 metal ion Inorganic materials 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 210000004877 mucosa Anatomy 0.000 description 4
• 230000008764 nerve damage Effects 0.000 description 4
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
• 229960002969 oleic acid Drugs 0.000 description 4
• 235000008390 olive oil Nutrition 0.000 description 4
• 210000001328 optic nerve Anatomy 0.000 description 4
• MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 description 4
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 4
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 4
• 229920002647 polyamide Polymers 0.000 description 4
• 229920001610 polycaprolactone Polymers 0.000 description 4
• 229920000515 polycarbonate Polymers 0.000 description 4
• 229920000573 polyethylene Polymers 0.000 description 4
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
• 229920001282 polysaccharide Polymers 0.000 description 4
• 239000005017 polysaccharide Substances 0.000 description 4
• 150000004804 polysaccharides Chemical class 0.000 description 4
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
• 229920000915 polyvinyl chloride Polymers 0.000 description 4
• 239000004800 polyvinyl chloride Substances 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 229960004063 propylene glycol Drugs 0.000 description 4
• 230000002685 pulmonary effect Effects 0.000 description 4
• ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 4
• 230000002207 retinal effect Effects 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 239000001509 sodium citrate Substances 0.000 description 4
• 150000003431 steroids Chemical class 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical group O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
• VPBYZLCHOKSGRX-UHFFFAOYSA-N 1-[2-chloro-4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-propylurea Chemical compound C1=C(Cl)C(NC(=O)NCCC)=CC=C1OC1=NC=NC2=CC(OC)=C(OC)C=C12 VPBYZLCHOKSGRX-UHFFFAOYSA-N 0.000 description 3
• 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 3
• RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 3
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
• 208000007465 Giant cell arteritis Diseases 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 208000029523 Interstitial Lung disease Diseases 0.000 description 3
• 206010022941 Iridocyclitis Diseases 0.000 description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 description 3
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
• XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 3
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 206010025415 Macular oedema Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 208000003435 Optic Neuritis Diseases 0.000 description 3
• 229920002732 Polyanhydride Polymers 0.000 description 3
• 229920001710 Polyorthoester Polymers 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 208000021386 Sjogren Syndrome Diseases 0.000 description 3
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 150000001298 alcohols Chemical class 0.000 description 3
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 201000004612 anterior uveitis Diseases 0.000 description 3
• 239000000440 bentonite Substances 0.000 description 3
• 229910000278 bentonite Inorganic materials 0.000 description 3
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 239000000560 biocompatible material Substances 0.000 description 3
• 239000001506 calcium phosphate Substances 0.000 description 3
• 239000004359 castor oil Substances 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
• 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 230000010405 clearance mechanism Effects 0.000 description 3
• 210000004087 cornea Anatomy 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 239000008380 degradant Substances 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 210000004207 dermis Anatomy 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 3
• 208000011325 dry age related macular degeneration Diseases 0.000 description 3
• 229960005167 everolimus Drugs 0.000 description 3
• 208000030533 eye disease Diseases 0.000 description 3
• 229940012356 eye drops Drugs 0.000 description 3
• FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 230000009368 gene silencing by RNA Effects 0.000 description 3
• 229950007540 glesatinib Drugs 0.000 description 3
• 229940075507 glyceryl monostearate Drugs 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 208000025750 heavy chain disease Diseases 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 210000000554 iris Anatomy 0.000 description 3
• 206010023332 keratitis Diseases 0.000 description 3
• MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 238000011068 loading method Methods 0.000 description 3
• 201000010230 macular retinal edema Diseases 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 239000011859 microparticle Substances 0.000 description 3
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
• RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 3
• 210000004400 mucous membrane Anatomy 0.000 description 3
• 201000005962 mycosis fungoides Diseases 0.000 description 3
• 206010028537 myelofibrosis Diseases 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 3
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
• 239000002070 nanowire Substances 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000011368 organic material Substances 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000006072 paste Substances 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 229960000639 pazopanib Drugs 0.000 description 3
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 3
• 239000002304 perfume Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 229960000502 poloxamer Drugs 0.000 description 3
• 229920000768 polyamine Polymers 0.000 description 3
• 229920000728 polyester Polymers 0.000 description 3
• 239000008389 polyethoxylated castor oil Substances 0.000 description 3
• 229920001296 polysiloxane Polymers 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 239000008159 sesame oil Substances 0.000 description 3
• 235000011803 sesame oil Nutrition 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 235000017550 sodium carbonate Nutrition 0.000 description 3
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
• 235000011083 sodium citrates Nutrition 0.000 description 3
• 239000008247 solid mixture Substances 0.000 description 3
• 235000011069 sorbitan monooleate Nutrition 0.000 description 3
• 239000001593 sorbitan monooleate Substances 0.000 description 3
• 229940035049 sorbitan monooleate Drugs 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000003765 sweetening agent Substances 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 230000004489 tear production Effects 0.000 description 3
• 206010043207 temporal arteritis Diseases 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 238000009827 uniform distribution Methods 0.000 description 3
• 210000001745 uvea Anatomy 0.000 description 3
• 230000004862 vasculogenesis Effects 0.000 description 3
• 230000000007 visual effect Effects 0.000 description 3
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
• ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 description 2
• XFWLTFZLLXVKDY-WAYWQWQTSA-N (z)-n,n'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine Chemical compound CCNCCCNC\C=C/CNCCCNCC XFWLTFZLLXVKDY-WAYWQWQTSA-N 0.000 description 2
• KILNVBDSWZSGLL-KXQOOQHDSA-O 1,2-di-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-O 0.000 description 2
• SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 2
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
• HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 2
• HJRDNARELSKHEF-CLFAGFIQSA-N 2-[2-[(z)-octadec-9-enoyl]oxyethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCOC(=O)CCCCCCC\C=C/CCCCCCCC HJRDNARELSKHEF-CLFAGFIQSA-N 0.000 description 2
• QLVSJMZJSABWRX-UHFFFAOYSA-N 2-[4-[6-amino-2-[[4-[[3-(cyclohexylamino)propylamino]methyl]cyclohexyl]methylamino]pyrimidin-4-yl]piperazin-1-yl]ethylphosphonic acid Chemical compound N=1C(N)=CC(N2CCN(CCP(O)(O)=O)CC2)=NC=1NCC(CC1)CCC1CNCCCNC1CCCCC1 QLVSJMZJSABWRX-UHFFFAOYSA-N 0.000 description 2
• CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
• FGTCROZDHDSNIO-UHFFFAOYSA-N 3-(4-quinolinylmethylamino)-N-[4-(trifluoromethoxy)phenyl]-2-thiophenecarboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(=O)C1=C(NCC=2C3=CC=CC=C3N=CC=2)C=CS1 FGTCROZDHDSNIO-UHFFFAOYSA-N 0.000 description 2
• HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 description 2
• GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 2
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 2
• CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
• 241000251468 Actinopterygii Species 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 239000005995 Aluminium silicate Substances 0.000 description 2
• YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 102400000068 Angiostatin Human genes 0.000 description 2
• 108010079709 Angiostatins Proteins 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
• 206010073360 Appendix cancer Diseases 0.000 description 2
• 244000105624 Arachis hypogaea Species 0.000 description 2
• 235000010777 Arachis hypogaea Nutrition 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
• VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 2
• 201000003274 CINCA syndrome Diseases 0.000 description 2
• 201000004085 CLL/SLL Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000002691 Choroiditis Diseases 0.000 description 2
• 108010062306 Clostridium botulinum exoenzyme C3 Proteins 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 206010010741 Conjunctivitis Diseases 0.000 description 2
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 229920002785 Croscarmellose sodium Polymers 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010072224 Deficiency of the interleukin-1 receptor antagonist Diseases 0.000 description 2
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
• 102400001047 Endostatin Human genes 0.000 description 2
• 108010079505 Endostatins Proteins 0.000 description 2
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 208000024869 Goodpasture syndrome Diseases 0.000 description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 206010022557 Intermediate uveitis Diseases 0.000 description 2
• 206010023347 Keratoacanthoma Diseases 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
• 240000003183 Manihot esculenta Species 0.000 description 2
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
• 208000014767 Myeloproliferative disease Diseases 0.000 description 2
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 206010067013 Normal tension glaucoma Diseases 0.000 description 2
• 240000007817 Olea europaea Species 0.000 description 2
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
• 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
• 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 2
• 108010082093 Placenta Growth Factor Proteins 0.000 description 2
• 102100035194 Placenta growth factor Human genes 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 102000004211 Platelet factor 4 Human genes 0.000 description 2
• 108090000778 Platelet factor 4 Proteins 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 229920001257 Poly(D,L-lactide-co-PEO-co-D,L-lactide) Polymers 0.000 description 2
• 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 2
• 229920001305 Poly(isodecyl(meth)acrylate) Polymers 0.000 description 2
• 229920002319 Poly(methyl acrylate) Polymers 0.000 description 2
• 229920001283 Polyalkylene terephthalate Polymers 0.000 description 2
• 239000004642 Polyimide Substances 0.000 description 2
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 229920001214 Polysorbate 60 Polymers 0.000 description 2
• 229920002396 Polyurea Polymers 0.000 description 2
• 239000004372 Polyvinyl alcohol Substances 0.000 description 2
• 208000003971 Posterior uveitis Diseases 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
• 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 2
• 108010057464 Prolactin Proteins 0.000 description 2
• 102000003946 Prolactin Human genes 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
• 108091030071 RNAI Proteins 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 235000004443 Ricinus communis Nutrition 0.000 description 2
• 241001303601 Rosacea Species 0.000 description 2
• 108091006629 SLC13A2 Proteins 0.000 description 2
• 235000019485 Safflower oil Nutrition 0.000 description 2
• 206010039705 Scleritis Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
• IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
• 239000004147 Sorbitan trioleate Substances 0.000 description 2
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 102000002938 Thrombospondin Human genes 0.000 description 2
• 108060008245 Thrombospondin Proteins 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 238000002441 X-ray diffraction Methods 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 2
• JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 208000017733 acquired polycythemia vera Diseases 0.000 description 2
• 150000001253 acrylic acids Chemical class 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 229960002833 aflibercept Drugs 0.000 description 2
• 229920013820 alkyl cellulose Polymers 0.000 description 2
• 150000005215 alkyl ethers Chemical class 0.000 description 2
• 208000002205 allergic conjunctivitis Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 229940003677 alphagan Drugs 0.000 description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 235000012211 aluminium silicate Nutrition 0.000 description 2
• 101150087739 amd gene Proteins 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 229960001232 anecortave Drugs 0.000 description 2
• 230000000964 angiostatic effect Effects 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000001772 anti-angiogenic effect Effects 0.000 description 2
• 230000000845 anti-microbial effect Effects 0.000 description 2
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
• 208000021780 appendiceal neoplasm Diseases 0.000 description 2
• 210000001742 aqueous humor Anatomy 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 208000024998 atopic conjunctivitis Diseases 0.000 description 2
• 229960003005 axitinib Drugs 0.000 description 2
• 210000002469 basement membrane Anatomy 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 229960003679 brimonidine Drugs 0.000 description 2
• 229940041504 bromday Drugs 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• 239000008366 buffered solution Substances 0.000 description 2
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
• PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 2
• 235000019437 butane-1,3-diol Nutrition 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229960005069 calcium Drugs 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
• 235000013539 calcium stearate Nutrition 0.000 description 2
• 239000008116 calcium stearate Substances 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 208000035269 cancer or benign tumor Diseases 0.000 description 2
• 235000019438 castor oil Nutrition 0.000 description 2
• 229920002301 cellulose acetate Polymers 0.000 description 2
• 229920003086 cellulose ether Polymers 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 229960002798 cetrimide Drugs 0.000 description 2
• WMEMLXDTLKSUOD-OGCOPIPOSA-N chembl436844 Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@@H](CC=2C3=CC=CC=C3N(C)C=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](C)C(=O)N1)C(C)C)=O)NC(=O)[C@@H](NC(C)=O)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 WMEMLXDTLKSUOD-OGCOPIPOSA-N 0.000 description 2
• XRZYELWZLNAXGE-KPKJPENVSA-N chembl539947 Chemical compound CC(C)(C)C1=CC(\C=C(/C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 2
• 229960004926 chlorobutanol Drugs 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
• 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 2
• 210000004240 ciliary body Anatomy 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 210000000795 conjunctiva Anatomy 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 235000005822 corn Nutrition 0.000 description 2
• 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 235000019700 dicalcium phosphate Nutrition 0.000 description 2
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
• 229940038472 dicalcium phosphate Drugs 0.000 description 2
• 229960001259 diclofenac Drugs 0.000 description 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
• SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 238000009837 dry grinding Methods 0.000 description 2
• 229960001484 edetic acid Drugs 0.000 description 2
• 239000002702 enteric coating Substances 0.000 description 2
• 238000009505 enteric coating Methods 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 235000019688 fish Nutrition 0.000 description 2
• 229960001347 fluocinolone acetonide Drugs 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
• 229940068939 glyceryl monolaurate Drugs 0.000 description 2
• 150000002334 glycols Chemical class 0.000 description 2
• 239000003979 granulating agent Substances 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 238000000265 homogenisation Methods 0.000 description 2
• 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
• 201000001421 hyperglycemia Diseases 0.000 description 2
• ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 239000003018 immunosuppressive agent Substances 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000007972 injectable composition Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 229940005319 inlyta Drugs 0.000 description 2
• 210000005007 innate immune system Anatomy 0.000 description 2
• 229910010272 inorganic material Inorganic materials 0.000 description 2
• 239000011147 inorganic material Substances 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 230000004410 intraocular pressure Effects 0.000 description 2
• 230000009545 invasion Effects 0.000 description 2
• 229920000831 ionic polymer Polymers 0.000 description 2
• 201000004614 iritis Diseases 0.000 description 2
• NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
• XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 2
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
• 229960004891 lapatinib Drugs 0.000 description 2
• GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 2
• 229960003744 loteprednol etabonate Drugs 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 201000002978 low tension glaucoma Diseases 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 229940076783 lucentis Drugs 0.000 description 2
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
• 239000000347 magnesium hydroxide Substances 0.000 description 2
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 210000004175 meibomian gland Anatomy 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 229960002216 methylparaben Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 2
• 239000002073 nanorod Substances 0.000 description 2
• 238000002663 nebulization Methods 0.000 description 2
• 238000013188 needle biopsy Methods 0.000 description 2
• 210000005170 neoplastic cell Anatomy 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 208000029974 neurofibrosarcoma Diseases 0.000 description 2
• 229940080607 nexavar Drugs 0.000 description 2
• 229960004378 nintedanib Drugs 0.000 description 2
• XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 235000014571 nuts Nutrition 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 201000008106 ocular cancer Diseases 0.000 description 2
• 235000021313 oleic acid Nutrition 0.000 description 2
• 229940055577 oleyl alcohol Drugs 0.000 description 2
• XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
• 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 208000020911 optic nerve disease Diseases 0.000 description 2
• 125000006353 oxyethylene group Chemical group 0.000 description 2
• 229940083224 ozurdex Drugs 0.000 description 2
• 239000003002 pH adjusting agent Substances 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 238000012856 packing Methods 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 230000000737 periodic effect Effects 0.000 description 2
• 229960003742 phenol Drugs 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• 229940067107 phenylethyl alcohol Drugs 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 235000011007 phosphoric acid Nutrition 0.000 description 2
• 108090000102 pigment epithelium-derived factor Proteins 0.000 description 2
• 229950008499 plitidepsin Drugs 0.000 description 2
• UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 2
• 108010049948 plitidepsin Proteins 0.000 description 2
• 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 2
• 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 2
• 229920001253 poly(D,L-lactide-co-caprolactone-co-glycolide) Polymers 0.000 description 2
• 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
• 229920000111 poly(butyric acid) Polymers 0.000 description 2
• 229920001279 poly(ester amides) Polymers 0.000 description 2
• 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 2
• 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 2
• 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 2
• 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 2
• 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
• 229920002492 poly(sulfone) Polymers 0.000 description 2
• 229920001197 polyacetylene Polymers 0.000 description 2
• 229920000058 polyacrylate Polymers 0.000 description 2
• 229920002239 polyacrylonitrile Polymers 0.000 description 2
• 229920001281 polyalkylene Polymers 0.000 description 2
• 229920001515 polyalkylene glycol Polymers 0.000 description 2
• 229920001230 polyarylate Polymers 0.000 description 2
• 208000037244 polycythemia vera Diseases 0.000 description 2
• 239000000622 polydioxanone Substances 0.000 description 2
• 229920000570 polyether Polymers 0.000 description 2
• 229920000139 polyethylene terephthalate Polymers 0.000 description 2
• 239000005020 polyethylene terephthalate Substances 0.000 description 2
• 229920002643 polyglutamic acid Polymers 0.000 description 2
• 229920000903 polyhydroxyalkanoate Polymers 0.000 description 2
• 229920001721 polyimide Polymers 0.000 description 2
• 229920001228 polyisocyanate Polymers 0.000 description 2
• 239000005056 polyisocyanate Substances 0.000 description 2
• 229920000197 polyisopropyl acrylate Polymers 0.000 description 2
• 229920000193 polymethacrylate Polymers 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
• 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
• 229920006324 polyoxymethylene Polymers 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 229920001299 polypropylene fumarate Polymers 0.000 description 2
• 229950008882 polysorbate Drugs 0.000 description 2
• 229940068984 polyvinyl alcohol Drugs 0.000 description 2
• 229920001290 polyvinyl ester Polymers 0.000 description 2
• 229920001289 polyvinyl ether Polymers 0.000 description 2
• 229920001291 polyvinyl halide Polymers 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
• 229940043349 potassium metabisulfite Drugs 0.000 description 2
• 235000010263 potassium metabisulphite Nutrition 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 201000007271 pre-malignant neoplasm Diseases 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 208000003476 primary myelofibrosis Diseases 0.000 description 2
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
• 229940097325 prolactin Drugs 0.000 description 2
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 235000019260 propionic acid Nutrition 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 239000002096 quantum dot Substances 0.000 description 2
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
• 229960003876 ranibizumab Drugs 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 206010038038 rectal cancer Diseases 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 201000004700 rosacea Diseases 0.000 description 2
• 239000003813 safflower oil Substances 0.000 description 2
• 235000005713 safflower oil Nutrition 0.000 description 2
• 210000003786 sclera Anatomy 0.000 description 2
• 229950003647 semaxanib Drugs 0.000 description 2
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 2
• 150000004760 silicates Chemical class 0.000 description 2
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 229920002545 silicone oil Polymers 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 235000010413 sodium alginate Nutrition 0.000 description 2
• 239000000661 sodium alginate Substances 0.000 description 2
• 229940005550 sodium alginate Drugs 0.000 description 2
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
• 235000010234 sodium benzoate Nutrition 0.000 description 2
• 239000004299 sodium benzoate Substances 0.000 description 2
• 229940001607 sodium bisulfite Drugs 0.000 description 2
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
• 229940001584 sodium metabisulfite Drugs 0.000 description 2
• 235000010262 sodium metabisulphite Nutrition 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 235000011008 sodium phosphates Nutrition 0.000 description 2
• 229920003109 sodium starch glycolate Polymers 0.000 description 2
• 229940079832 sodium starch glycolate Drugs 0.000 description 2
• 239000008109 sodium starch glycolate Substances 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• 229960003787 sorafenib Drugs 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 229940035044 sorbitan monolaurate Drugs 0.000 description 2
• 235000019337 sorbitan trioleate Nutrition 0.000 description 2
• 229960000391 sorbitan trioleate Drugs 0.000 description 2
• 235000011078 sorbitan tristearate Nutrition 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 238000001179 sorption measurement Methods 0.000 description 2
• 239000003549 soybean oil Substances 0.000 description 2
• 235000012424 soybean oil Nutrition 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• 229940012831 stearyl alcohol Drugs 0.000 description 2
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 238000009168 stem cell therapy Methods 0.000 description 2
• 238000009580 stem-cell therapy Methods 0.000 description 2
• 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 description 2
• 235000020238 sunflower seed Nutrition 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 229920001059 synthetic polymer Polymers 0.000 description 2
• 229950010924 talaporfin Drugs 0.000 description 2
• 229960003433 thalidomide Drugs 0.000 description 2
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
• 229960000707 tobramycin Drugs 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
• YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
• 229960000241 vandetanib Drugs 0.000 description 2
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 239000002525 vasculotropin inhibitor Substances 0.000 description 2
• 239000004034 viscosity adjusting agent Substances 0.000 description 2
• 239000011709 vitamin E Substances 0.000 description 2
• 229940046009 vitamin E Drugs 0.000 description 2
• 210000004127 vitreous body Anatomy 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
• FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
• WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 1
• MYZAXBZLEILEBR-RVFOSREFSA-N (2S)-1-[(2S,3R)-2-[[(2R)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-sulfopropanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](CS(O)(=O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O MYZAXBZLEILEBR-RVFOSREFSA-N 0.000 description 1
• PQEJXGNZBLONLG-XJDOXCRVSA-N (2r)-2-amino-3-[1-[3-[2-[4-[1,3-bis(2-methoxyethylcarbamoyloxy)propan-2-yloxy]butanoylamino]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O PQEJXGNZBLONLG-XJDOXCRVSA-N 0.000 description 1
• UHXXJVYBIFPFFQ-DKWTVANSSA-N (2r)-2-amino-3-sulfanylpropanoic acid;zinc Chemical class [Zn].SC[C@H](N)C(O)=O UHXXJVYBIFPFFQ-DKWTVANSSA-N 0.000 description 1
• MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
• KGWWHPZQLVVAPT-STTJLUEPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(\C=C\C=2C=CC=CC=2)=N1 KGWWHPZQLVVAPT-STTJLUEPSA-N 0.000 description 1
• YOKBGCTZYPOSQM-HPSWDUTRSA-N (2s)-2-acetamido-n-[(3s,9s,12s,15r,18s)-15-(cyclohexylmethyl)-9-[3-(diaminomethylideneamino)propyl]-12-(1h-indol-3-ylmethyl)-2,8,11,14,17-pentaoxo-1,7,10,13,16-pentazabicyclo[16.3.0]henicosan-3-yl]-3-phenylpropanamide Chemical compound C([C@H](NC(=O)C)C(=O)N[C@@H]1C(N2CCC[C@H]2C(=O)N[C@H](CC2CCCCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC1)=O)C1=CC=CC=C1 YOKBGCTZYPOSQM-HPSWDUTRSA-N 0.000 description 1
• JOTNXPXOZZACQR-MDJKOFFZSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;chloromethyl (8s,9s,10r,11s,13s,14s,17r)-17-ethoxycarbonyloxy-11-hydroxy-10,13 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JOTNXPXOZZACQR-MDJKOFFZSA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
• CSGQVNMSRKWUSH-IAGOWNOFSA-N (3r,4r)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol Chemical compound COC1=CC=CC(NC=2C3=C(CN4C[C@@H](O)[C@H](N)CC4)C=CN3N=CN=2)=C1 CSGQVNMSRKWUSH-IAGOWNOFSA-N 0.000 description 1
• HGHOBRRUMWJWCU-FXQIFTODSA-N (4s)-4-[[(2s)-2-aminopropanoyl]amino]-5-[[(2s)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O HGHOBRRUMWJWCU-FXQIFTODSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
• FFXUDLUXUIJFSS-NTCAYCPXSA-N (e)-3-[1-[2-(diethylamino)ethyl]-2-(2-phenylethyl)benzimidazol-5-yl]-n-hydroxyprop-2-enamide Chemical compound N=1C2=CC(\C=C\C(=O)NO)=CC=C2N(CCN(CC)CC)C=1CCC1=CC=CC=C1 FFXUDLUXUIJFSS-NTCAYCPXSA-N 0.000 description 1
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
• QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
• DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• ZXBFYBLSJMEBEP-UHFFFAOYSA-N 1-[1-[(2-aminopyridin-4-yl)methyl]indol-4-yl]-3-(5-bromo-2-methoxyphenyl)urea Chemical compound COC1=CC=C(Br)C=C1NC(=O)NC1=CC=CC2=C1C=CN2CC1=CC=NC(N)=C1 ZXBFYBLSJMEBEP-UHFFFAOYSA-N 0.000 description 1
• KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 description 1
• RROLKYCVTJGMND-UHFFFAOYSA-N 1-acetyl-5-hydroxyanthracene-9,10-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C=CC=C2C(=O)C RROLKYCVTJGMND-UHFFFAOYSA-N 0.000 description 1
• YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• WGIMXKDCVCTHGW-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCO WGIMXKDCVCTHGW-UHFFFAOYSA-N 0.000 description 1
• RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
• FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
• VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
• MOKBFXZQXUZAMV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCO MOKBFXZQXUZAMV-UHFFFAOYSA-N 0.000 description 1
• YUFAHBUWIVNVNJ-UHFFFAOYSA-N 2-[4-(1,2-diphenylbutyl)phenoxy]-n,n-dimethylethanamine Chemical compound C=1C=CC=CC=1C(CC)C(C=1C=CC(OCCN(C)C)=CC=1)C1=CC=CC=C1 YUFAHBUWIVNVNJ-UHFFFAOYSA-N 0.000 description 1
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
• PFMPOBVAYMTUOX-GOSISDBHSA-N 2-amino-1-ethyl-7-[(3r)-3-hydroxy-4-methoxy-3-methylbut-1-ynyl]-n-methyl-4-oxo-1,8-naphthyridine-3-carboxamide Chemical compound C1=C(C#C[C@@](C)(O)COC)N=C2N(CC)C(N)=C(C(=O)NC)C(=O)C2=C1 PFMPOBVAYMTUOX-GOSISDBHSA-N 0.000 description 1
• FIDMEHCRMLKKPZ-YSMBQZINSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] dihydrogen phosphate Chemical compound OCC(N)(CO)CO.C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 FIDMEHCRMLKKPZ-YSMBQZINSA-N 0.000 description 1
• OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
• QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
• KQIKOUUKQBTQBE-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KQIKOUUKQBTQBE-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• ZSPTYLOMNJNZNG-UHFFFAOYSA-N 3-Buten-1-ol Chemical group OCCC=C ZSPTYLOMNJNZNG-UHFFFAOYSA-N 0.000 description 1
• UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
• MROGTPNQSHMKIG-UHFFFAOYSA-N 4-[4-(2-aminopropan-2-yl)phenyl]-2-[4-(2-morpholin-4-ylethyl)anilino]pyrimidine-5-carbonitrile Chemical compound C1=CC(C(C)(N)C)=CC=C1C1=NC(NC=2C=CC(CCN3CCOCC3)=CC=2)=NC=C1C#N MROGTPNQSHMKIG-UHFFFAOYSA-N 0.000 description 1
• QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 description 1
• OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
• SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• ZTCJXHNJVLUUMR-UHFFFAOYSA-N 4-iodo-6-phenylpyrimidine Chemical compound C1=NC(I)=CC(C=2C=CC=CC=2)=N1 ZTCJXHNJVLUUMR-UHFFFAOYSA-N 0.000 description 1
• GPSZYOIFQZPWEJ-UHFFFAOYSA-N 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=CC(=CC=3)N3CCOCC3)N=CC=2)=C1C GPSZYOIFQZPWEJ-UHFFFAOYSA-N 0.000 description 1
• JWUOZHTYFQHGAB-UHFFFAOYSA-N 5-[(4-prop-2-ynylpiperazin-1-yl)methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN1CCN(CC#C)CC1 JWUOZHTYFQHGAB-UHFFFAOYSA-N 0.000 description 1
• CTNPALGJUAXMMC-PMFHANACSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-n-[(2s)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound C([C@@H](O)CNC(=O)C=1C(C)=C(\C=C/2C3=CC(F)=CC=C3NC\2=O)NC=1C)N1CCOCC1 CTNPALGJUAXMMC-PMFHANACSA-N 0.000 description 1
• NRPIRIUWEKTNGQ-UHFFFAOYSA-N 5-amino-2-[2,6-di(propan-2-yl)phenyl]isoindole-1,3-dione Chemical compound CC(C)C1=CC=CC(C(C)C)=C1N1C(=O)C2=CC(N)=CC=C2C1=O NRPIRIUWEKTNGQ-UHFFFAOYSA-N 0.000 description 1
• AQOKCDNYWBIDND-ABRBVVEGSA-N 5-trans-17-phenyl trinor Prostaglandin F2alpha ethyl amide Chemical compound CCNC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-ABRBVVEGSA-N 0.000 description 1
• YEAHTLOYHVWAKW-UHFFFAOYSA-N 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one Chemical compound C1=CC(OC)=CC=C1COC(C(=C1)OC)=CC2=C1C1=CC=C(C(C)O)C=C1C(=O)O2 YEAHTLOYHVWAKW-UHFFFAOYSA-N 0.000 description 1
• ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
• 108010048280 AcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg) Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010000591 Acrochordon Diseases 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
• 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
• 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
• 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 229910001316 Ag alloy Inorganic materials 0.000 description 1
• 240000006054 Agastache cana Species 0.000 description 1
• 235000006667 Aleurites moluccana Nutrition 0.000 description 1
• 244000136475 Aleurites moluccana Species 0.000 description 1
• 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
• 208000035939 Alveolitis allergic Diseases 0.000 description 1
• 206010060937 Amniotic cavity infection Diseases 0.000 description 1
• APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 235000011437 Amygdalus communis Nutrition 0.000 description 1
• 244000144730 Amygdalus persica Species 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 208000000058 Anaplasia Diseases 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 101000583077 Anemonia viridis Delta-actitoxin-Avd1c 1 Proteins 0.000 description 1
• 101001023084 Anemonia viridis Delta-actitoxin-Avd1c 2 Proteins 0.000 description 1
• 101001023068 Anemonia viridis Delta-actitoxin-Avd1c 3 Proteins 0.000 description 1
• 102000008076 Angiogenic Proteins Human genes 0.000 description 1
• 108010074415 Angiogenic Proteins Proteins 0.000 description 1
• 102000009075 Angiopoietin-2 Human genes 0.000 description 1
• 108010048036 Angiopoietin-2 Proteins 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 102000004411 Antithrombin III Human genes 0.000 description 1
• 108090000935 Antithrombin III Proteins 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 235000003276 Apios tuberosa Nutrition 0.000 description 1
• 206010003011 Appendicitis Diseases 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 206010004485 Berylliosis Diseases 0.000 description 1
• 108050002823 Bestrophin Proteins 0.000 description 1
• 102000012304 Bestrophin Human genes 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 229930185605 Bisphenol Natural products 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 235000007689 Borago officinalis Nutrition 0.000 description 1
• 240000004355 Borago officinalis Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101100208237 Bos taurus THBS2 gene Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
• 240000002791 Brassica napus Species 0.000 description 1
• 235000006008 Brassica napus var napus Nutrition 0.000 description 1
• 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
• 244000188595 Brassica sinapistrum Species 0.000 description 1
• 235000004936 Bromus mango Nutrition 0.000 description 1
• 206010006448 Bronchiolitis Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 206010006811 Bursitis Diseases 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
• 108010001282 CT-322 Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
• 102100029968 Calreticulin Human genes 0.000 description 1
• 108090000549 Calreticulin Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102400000730 Canstatin Human genes 0.000 description 1
• 101800000626 Canstatin Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
• 244000020518 Carthamus tinctorius Species 0.000 description 1
• 235000005747 Carum carvi Nutrition 0.000 description 1
• 240000000467 Carum carvi Species 0.000 description 1
• 108010076119 Caseins Proteins 0.000 description 1
• 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 240000003538 Chamaemelum nobile Species 0.000 description 1
• 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 206010008617 Cholecystitis chronic Diseases 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 241000206575 Chondrus crispus Species 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000008158 Chorioamnionitis Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
• 102100031186 Chromogranin-A Human genes 0.000 description 1
• 208000023355 Chronic beryllium disease Diseases 0.000 description 1
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
• 241000132536 Cirsium Species 0.000 description 1
• YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
• 241000207199 Citrus Species 0.000 description 1
• 235000005979 Citrus limon Nutrition 0.000 description 1
• 244000131522 Citrus pyriformis Species 0.000 description 1
• 235000013162 Cocos nucifera Nutrition 0.000 description 1
• 244000060011 Cocos nucifera Species 0.000 description 1
• 102100024484 Codanin-1 Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
• 208000016134 Conjunctival disease Diseases 0.000 description 1
• 206010010736 Conjunctival ulcer Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 240000009226 Corylus americana Species 0.000 description 1
• 235000001543 Corylus americana Nutrition 0.000 description 1
• 235000007466 Corylus avellana Nutrition 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 240000001980 Cucurbita pepo Species 0.000 description 1
• 235000009852 Cucurbita pepo Nutrition 0.000 description 1
• 206010011715 Cyclitis Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 206010011732 Cyst Diseases 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• WVXNSAVVKYZVOE-UHFFFAOYSA-N DCC-2036 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C4C=CC=NC4=CC=3)=CC=2)=C1 WVXNSAVVKYZVOE-UHFFFAOYSA-N 0.000 description 1
• 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
• XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
• 239000004287 Dehydroacetic acid Substances 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
• WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
• 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
• 241000271571 Dromaius novaehollandiae Species 0.000 description 1
• OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
• QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
• 102000002322 Egg Proteins Human genes 0.000 description 1
• 108010000912 Egg Proteins Proteins 0.000 description 1
• 206010014476 Elevated cholesterol Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 208000004145 Endometritis Diseases 0.000 description 1
• 208000004232 Enteritis Diseases 0.000 description 1
• 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 201000011275 Epicondylitis Diseases 0.000 description 1
• 206010015084 Episcleritis Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 244000004281 Eucalyptus maculata Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 206010063560 Excessive granulation tissue Diseases 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 208000001860 Eye Infections Diseases 0.000 description 1
• 241000272190 Falco peregrinus Species 0.000 description 1
• 206010016228 Fasciitis Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• 239000005792 Geraniol Substances 0.000 description 1
• GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 244000060234 Gmelina philippensis Species 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 244000020551 Helianthus annuus Species 0.000 description 1
• 235000003222 Helianthus annuus Nutrition 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 240000000950 Hippophae rhamnoides Species 0.000 description 1
• 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
• 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
• 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
• 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
• 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
• 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
• 241000384508 Hoplostethus atlanticus Species 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 1
• 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 1
• 208000032578 Inherited retinal disease Diseases 0.000 description 1
• IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• 240000007049 Juglans regia Species 0.000 description 1
• 235000009496 Juglans regia Nutrition 0.000 description 1
• 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
• 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
• 206010023644 Lacrimation increased Diseases 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• 241000218652 Larix Species 0.000 description 1
• 235000005590 Larix decidua Nutrition 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 201000008197 Laryngitis Diseases 0.000 description 1
• 244000165082 Lavanda vera Species 0.000 description 1
• 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
• 241000408747 Lepomis gibbosus Species 0.000 description 1
• 240000003553 Leptospermum scoparium Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 241001072282 Limnanthes Species 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 235000012854 Litsea cubeba Nutrition 0.000 description 1
• 240000002262 Litsea cubeba Species 0.000 description 1
• 241001106041 Lycium Species 0.000 description 1
• 235000015459 Lycium barbarum Nutrition 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 241000282567 Macaca fascicularis Species 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 240000000982 Malva neglecta Species 0.000 description 1
• 235000000060 Malva neglecta Nutrition 0.000 description 1
• 235000014826 Mangifera indica Nutrition 0.000 description 1
• 240000007228 Mangifera indica Species 0.000 description 1
• 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 244000179970 Monarda didyma Species 0.000 description 1
• 235000010672 Monarda didyma Nutrition 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 208000012799 Mu-heavy chain disease Diseases 0.000 description 1
• 229920000715 Mucilage Polymers 0.000 description 1
• 108010093825 Mucoproteins Proteins 0.000 description 1
• 102000001621 Mucoproteins Human genes 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241000699729 Muridae Species 0.000 description 1
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
• 101000686934 Mus musculus Prolactin-7D1 Proteins 0.000 description 1
• 208000002231 Muscle Neoplasms Diseases 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 235000009421 Myristica fragrans Nutrition 0.000 description 1
• 244000270834 Myristica fragrans Species 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
• 102000004722 NADPH Oxidases Human genes 0.000 description 1
• 108010002998 NADPH Oxidases Proteins 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 241000772415 Neovison vison Species 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 102000002111 Neuropilin Human genes 0.000 description 1
• 108050009450 Neuropilin Proteins 0.000 description 1
• 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
• 102000011931 Nucleoproteins Human genes 0.000 description 1
• 108010061100 Nucleoproteins Proteins 0.000 description 1
• MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
• 206010030043 Ocular hypertension Diseases 0.000 description 1
• 241000219925 Oenothera Species 0.000 description 1
• 235000004496 Oenothera biennis Nutrition 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 206010061323 Optic neuropathy Diseases 0.000 description 1
• 235000014643 Orbignya martiana Nutrition 0.000 description 1
• 244000021150 Orbignya martiana Species 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 206010031149 Osteitis Diseases 0.000 description 1
• 102000004264 Osteopontin Human genes 0.000 description 1
• 108010081689 Osteopontin Proteins 0.000 description 1
• 208000005141 Otitis Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 208000017459 Paget disease of the penis Diseases 0.000 description 1
• 208000025610 Paget disease of the vulva Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 235000008753 Papaver somniferum Nutrition 0.000 description 1
• 206010034038 Parotitis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 244000025272 Persea americana Species 0.000 description 1
• 235000008673 Persea americana Nutrition 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
• 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
• 206010035742 Pneumonitis Diseases 0.000 description 1
• 229920002517 Poloxamer 338 Polymers 0.000 description 1
• 229920001267 Poly(D,L-lactide-co-PPO-co-D,L-lactide) Polymers 0.000 description 1
• 229920001212 Poly(beta amino esters) Polymers 0.000 description 1
• 229920002873 Polyethylenimine Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 206010036346 Posterior capsule opacification Diseases 0.000 description 1
• HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
• 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
• 208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
• 235000009827 Prunus armeniaca Nutrition 0.000 description 1
• 244000018633 Prunus armeniaca Species 0.000 description 1
• 235000006040 Prunus persica var persica Nutrition 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 206010037596 Pyelonephritis Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
• 102400001051 Restin Human genes 0.000 description 1
• 208000007135 Retinal Neovascularization Diseases 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 208000032430 Retinal dystrophy Diseases 0.000 description 1
• 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 229930189077 Rifamycin Natural products 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 244000178231 Rosmarinus officinalis Species 0.000 description 1
• 108010005173 SERPIN-B5 Proteins 0.000 description 1
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 208000007893 Salpingitis Diseases 0.000 description 1
• 240000000513 Santalum album Species 0.000 description 1
• 235000008632 Santalum album Nutrition 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 208000006938 Schwannomatosis Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 206010048810 Sebaceous hyperplasia Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 102100030333 Serpin B5 Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 244000040738 Sesamum orientale Species 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• 229910052581 Si3N4 Inorganic materials 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 244000044822 Simmondsia californica Species 0.000 description 1
• 235000004433 Simmondsia californica Nutrition 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 101710105463 Snake venom vascular endothelial growth factor toxin Proteins 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
• 235000009184 Spondias indica Nutrition 0.000 description 1
• UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
• UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 208000033809 Suppuration Diseases 0.000 description 1
• 108090000054 Syndecan-2 Proteins 0.000 description 1
• 201000008736 Systemic mastocytosis Diseases 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 102400000709 T2-TrpRS Human genes 0.000 description 1
• 101800000458 T2-TrpRS Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 241001455273 Tetrapoda Species 0.000 description 1
• 206010043515 Throat cancer Diseases 0.000 description 1
• 108010046722 Thrombospondin 1 Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
• 206010045240 Type I hypersensitivity Diseases 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000006374 Uterine Cervicitis Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 1
• 206010046914 Vaginal infection Diseases 0.000 description 1
• 201000008100 Vaginitis Diseases 0.000 description 1
• 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
• 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
• 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
• 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
• 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
• 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047124 Vasculitis necrotising Diseases 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• 235000007769 Vetiveria zizanioides Nutrition 0.000 description 1
• 244000284012 Vetiveria zizanioides Species 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
• 241001135917 Vitellaria paradoxa Species 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
• YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 239000000370 acceptor Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 229960000583 acetic acid Drugs 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000004064 acoustic neuroma Diseases 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 229940002946 acuvail Drugs 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 229940042992 afinitor Drugs 0.000 description 1
• 229950000920 aganirsen Drugs 0.000 description 1
• 238000005054 agglomeration Methods 0.000 description 1
• 108010084217 alanyl-glutamyl-aspartyl-glycine Proteins 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 235000020224 almond Nutrition 0.000 description 1
• 208000025751 alpha chain disease Diseases 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229960000711 alprostadil Drugs 0.000 description 1
• 229920005603 alternating copolymer Polymers 0.000 description 1
• 229940024545 aluminum hydroxide Drugs 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 150000001414 amino alcohols Chemical class 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 108010089411 angiocal protein Proteins 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000000843 anti-fungal effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000884 anti-protozoa Effects 0.000 description 1
• 239000000043 antiallergic agent Substances 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000003529 anticholesteremic agent Substances 0.000 description 1
• 229940127226 anticholesterol agent Drugs 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 229940125708 antidiabetic agent Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 229960005348 antithrombin iii Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 229960003982 apatinib Drugs 0.000 description 1
• 101150059062 apln gene Proteins 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
• 108010081641 arginyl-phenylalanyl-valyl-prolyl-aspartyl-glycyl-asparagyl-arginyl-isoleucine Proteins 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 238000000889 atomisation Methods 0.000 description 1
• 201000003308 autosomal dominant familial periodic fever Diseases 0.000 description 1
• PUKBOVABABRILL-YZNIXAGQSA-N avacopan Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1NC(=O)[C@@H]1[C@H](C=2C=CC(NC3CCCC3)=CC=2)N(C(=O)C=2C(=CC=CC=2C)F)CCC1 PUKBOVABABRILL-YZNIXAGQSA-N 0.000 description 1
• 150000003851 azoles Chemical class 0.000 description 1
• 201000007917 background diabetic retinopathy Diseases 0.000 description 1
• 235000001053 badasse Nutrition 0.000 description 1
• 238000000498 ball milling Methods 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
• 229950001858 batimastat Drugs 0.000 description 1
• 229960001950 benzethonium chloride Drugs 0.000 description 1
• UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 229950010015 bertilimumab Drugs 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 235000013734 beta-carotene Nutrition 0.000 description 1
• 239000011648 beta-carotene Substances 0.000 description 1
• TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 229960002747 betacarotene Drugs 0.000 description 1
• JKXXLIACMWFHSH-FIIWBELYSA-A bevasiranib sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C(NC(=O)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 JKXXLIACMWFHSH-FIIWBELYSA-A 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 150000001621 bismuth Chemical class 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000004378 blood-retinal barrier Effects 0.000 description 1
• 210000004155 blood-retinal barrier Anatomy 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 208000018339 bone inflammation disease Diseases 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 201000008274 breast adenocarcinoma Diseases 0.000 description 1
• 201000000135 breast papillary carcinoma Diseases 0.000 description 1
• 229960001724 brimonidine tartrate Drugs 0.000 description 1
• HZFGMQJYAFHESD-UHFFFAOYSA-M bromfenac sodium Chemical compound [Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 HZFGMQJYAFHESD-UHFFFAOYSA-M 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 201000005200 bronchus cancer Diseases 0.000 description 1
• 229960003168 bronopol Drugs 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 229950000814 burixafor Drugs 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 229940067596 butylparaben Drugs 0.000 description 1
• 229960001292 cabozantinib Drugs 0.000 description 1
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229960002713 calcium chloride Drugs 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
• 239000001354 calcium citrate Substances 0.000 description 1
• 229960004256 calcium citrate Drugs 0.000 description 1
• 229960002283 calcium glubionate Drugs 0.000 description 1
• 229940078512 calcium gluceptate Drugs 0.000 description 1
• 239000004227 calcium gluconate Substances 0.000 description 1
• 235000013927 calcium gluconate Nutrition 0.000 description 1
• 229960004494 calcium gluconate Drugs 0.000 description 1
• UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
• 229940095618 calcium glycerophosphate Drugs 0.000 description 1
• 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
• MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
• 239000001527 calcium lactate Substances 0.000 description 1
• 235000011086 calcium lactate Nutrition 0.000 description 1
• 229960002401 calcium lactate Drugs 0.000 description 1
• 229940078480 calcium levulinate Drugs 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 235000011132 calcium sulphate Nutrition 0.000 description 1
• FATUQANACHZLRT-XBQZYUPDSA-L calcium;(2r,3r,4s,5r,6r)-2,3,4,5,6,7-hexahydroxyheptanoate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C([O-])=O FATUQANACHZLRT-XBQZYUPDSA-L 0.000 description 1
• OKRXSXDSNLJCRS-NLOQLBMISA-L calcium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate;hydrate Chemical compound O.[Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O OKRXSXDSNLJCRS-NLOQLBMISA-L 0.000 description 1
• NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229960001838 canakinumab Drugs 0.000 description 1
• 229940041011 carbapenems Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
• WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
• 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
• 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
• 229940096529 carboxypolymethylene Drugs 0.000 description 1
• 208000002458 carcinoid tumor Diseases 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 239000005018 casein Substances 0.000 description 1
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
• 235000021240 caseins Nutrition 0.000 description 1
• 229940047475 cataflam Drugs 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 229940023913 cation exchange resins Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• MLIFNJABMANKEU-UHFFFAOYSA-N cep-5214 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCO)C4=C3CC2=C1 MLIFNJABMANKEU-UHFFFAOYSA-N 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 239000000919 ceramic Substances 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 206010008323 cervicitis Diseases 0.000 description 1
• 229960000800 cetrimonium bromide Drugs 0.000 description 1
• 229910052729 chemical element Inorganic materials 0.000 description 1
• 208000010575 cherry hemangioma Diseases 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 229960003260 chlorhexidine Drugs 0.000 description 1
• 229960002242 chlorocresol Drugs 0.000 description 1
• 229960005443 chloroxylenol Drugs 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 208000003167 cholangitis Diseases 0.000 description 1
• 201000001352 cholecystitis Diseases 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• ZKZKCEAHVFVZDJ-MTUMARHDSA-N cilofungin Chemical compound C1=CC(OCCCCCCCC)=CC=C1C(=O)N[C@@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C1 ZKZKCEAHVFVZDJ-MTUMARHDSA-N 0.000 description 1
• 229950007664 cilofungin Drugs 0.000 description 1
• 108010090182 cilofungin Proteins 0.000 description 1
• 235000017803 cinnamon Nutrition 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 229960002303 citric acid monohydrate Drugs 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 239000011247 coating layer Substances 0.000 description 1
• 235000019516 cod Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 201000010918 connective tissue cancer Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 229940108928 copper Drugs 0.000 description 1
• 239000011258 core-shell material Substances 0.000 description 1
• 201000007717 corneal ulcer Diseases 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229930003836 cresol Natural products 0.000 description 1
• 229940013361 cresol Drugs 0.000 description 1
• 229960005168 croscarmellose Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 238000009646 cryomilling Methods 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• 229940086555 cyclomethicone Drugs 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• 230000002380 cytological effect Effects 0.000 description 1
• 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 1
• 201000004400 dacryoadenitis Diseases 0.000 description 1
• 229950009076 dalantercept Drugs 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 235000019258 dehydroacetic acid Nutrition 0.000 description 1
• 229940061632 dehydroacetic acid Drugs 0.000 description 1
• 239000000412 dendrimer Substances 0.000 description 1
• 229920000736 dendritic polymer Polymers 0.000 description 1
• 238000001739 density measurement Methods 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 201000009803 desquamative interstitial pneumonia Diseases 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
• 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
• 229920000359 diblock copolymer Polymers 0.000 description 1
• CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 229960004875 difluprednate Drugs 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 229940008099 dimethicone Drugs 0.000 description 1
• AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
• 239000004205 dimethyl polysiloxane Substances 0.000 description 1
• 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
• 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 229960002563 disulfiram Drugs 0.000 description 1
• WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
• 229960000878 docusate sodium Drugs 0.000 description 1
• IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
• 229960003933 dorzolamide Drugs 0.000 description 1
• 229950005778 dovitinib Drugs 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 208000019258 ear infection Diseases 0.000 description 1
• 238000013399 early diagnosis Methods 0.000 description 1
• 229960002224 eculizumab Drugs 0.000 description 1
• 229940009662 edetate Drugs 0.000 description 1
• 229940013191 edex Drugs 0.000 description 1
• 235000013345 egg yolk Nutrition 0.000 description 1
• 210000002969 egg yolk Anatomy 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 230000009881 electrostatic interaction Effects 0.000 description 1
• 229950004717 elpamotide Drugs 0.000 description 1
• ZAJHBCDPAUKEPU-GIKXZWSFSA-N elpamotide Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)CC1=CC=CC=C1 ZAJHBCDPAUKEPU-GIKXZWSFSA-N 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 201000011025 embryonal testis carcinoma Diseases 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008393 encapsulating agent Substances 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 208000010227 enterocolitis Diseases 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• OSUHJPCHFDQAIT-UHFFFAOYSA-N ethyl 2-{4-[(6-chloroquinoxalin-2-yl)oxy]phenoxy}propanoate Chemical compound C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=CN=C(C=C(Cl)C=C2)C2=N1 OSUHJPCHFDQAIT-UHFFFAOYSA-N 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
• 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
• NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 208000011323 eye infectious disease Diseases 0.000 description 1
• 229940051306 eylea Drugs 0.000 description 1
• 210000000887 face Anatomy 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 229950003662 fenretinide Drugs 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000013020 final formulation Substances 0.000 description 1
• 235000004426 flaxseed Nutrition 0.000 description 1
• XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
• 229960004413 flucytosine Drugs 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 229950008692 foretinib Drugs 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 201000006321 fundus dystrophy Diseases 0.000 description 1
• 208000024386 fungal infectious disease Diseases 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
• 229960004675 fusidic acid Drugs 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 229940113087 geraniol Drugs 0.000 description 1
• 201000003115 germ cell cancer Diseases 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 229950006191 gluconic acid Drugs 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
• 210000001126 granulation tissue Anatomy 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 229940087559 grape seed Drugs 0.000 description 1
• LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 235000019314 gum ghatti Nutrition 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 229960004867 hexetidine Drugs 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 108700014293 human ALK1-Fc fusion Proteins 0.000 description 1
• 102000045556 human ALK1-Fc fusion Human genes 0.000 description 1
• 102000058223 human VEGFA Human genes 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 239000010903 husk Substances 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000005661 hydrophobic surface Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 229950006359 icrucumab Drugs 0.000 description 1
• 229960004716 idoxuridine Drugs 0.000 description 1
• 208000009326 ileitis Diseases 0.000 description 1
• 229940029200 iluvien Drugs 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 229940113174 imidurea Drugs 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 238000002664 inhalation therapy Methods 0.000 description 1
• 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 229910001867 inorganic solvent Inorganic materials 0.000 description 1
• 239000003049 inorganic solvent Substances 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 229960001388 interferon-beta Drugs 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 239000001282 iso-butane Substances 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229940074928 isopropyl myristate Drugs 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 229960004130 itraconazole Drugs 0.000 description 1
• 229940090046 jet injector Drugs 0.000 description 1
• 238000010902 jet-milling Methods 0.000 description 1
• UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 description 1
• 229960004384 ketorolac tromethamine Drugs 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000004561 lacrimal apparatus Anatomy 0.000 description 1
• 239000000832 lactitol Substances 0.000 description 1
• VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
• 235000010448 lactitol Nutrition 0.000 description 1
• 229960003451 lactitol Drugs 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 238000013532 laser treatment Methods 0.000 description 1
• 229960001160 latanoprost Drugs 0.000 description 1
• 244000056931 lavandin Species 0.000 description 1
• 235000009606 lavandin Nutrition 0.000 description 1
• 239000001102 lavandula vera Substances 0.000 description 1
• 235000018219 lavender Nutrition 0.000 description 1
• 206010024217 lentigo Diseases 0.000 description 1
• 229960003784 lenvatinib Drugs 0.000 description 1
• WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
• 235000005772 leucine Nutrition 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229950002216 linifanib Drugs 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 238000005461 lubrication Methods 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 201000003265 lymphadenitis Diseases 0.000 description 1
• 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
• 230000035168 lymphangiogenesis Effects 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 208000005158 lymphoid interstitial pneumonia Diseases 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229940041033 macrolides Drugs 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 229940092110 macugen Drugs 0.000 description 1
• 229960000816 magnesium hydroxide Drugs 0.000 description 1
• 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
• HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
• 208000021937 marginal zone lymphoma Diseases 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
• 108091008602 mbVEGFR Proteins 0.000 description 1
• IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
• 229960002525 mecamylamine Drugs 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 208000030163 medullary breast carcinoma Diseases 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 210000001704 mesoblast Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 238000001531 micro-dissection Methods 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 244000000010 microbial pathogen Species 0.000 description 1
• 108010068982 microplasmin Proteins 0.000 description 1
• 206010063344 microscopic polyangiitis Diseases 0.000 description 1
• 229950010895 midostaurin Drugs 0.000 description 1
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 244000309715 mini pig Species 0.000 description 1
• 235000013379 molasses Nutrition 0.000 description 1
• 229940041009 monobactams Drugs 0.000 description 1
• 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
• 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
• 229950003968 motesanib Drugs 0.000 description 1
• RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
• 208000026114 mu chain disease Diseases 0.000 description 1
• 208000022669 mucinous neoplasm Diseases 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 201000002077 muscle cancer Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
• WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
• 239000002074 nanoribbon Substances 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 239000002071 nanotube Substances 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 210000000581 natural killer T-cell Anatomy 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 230000002956 necrotizing effect Effects 0.000 description 1
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
• 230000017066 negative regulation of growth Effects 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 229960001002 nepafenac Drugs 0.000 description 1
• QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 201000009494 neurilemmomatosis Diseases 0.000 description 1
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• 210000002445 nipple Anatomy 0.000 description 1
• MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
• IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical class NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 239000001702 nutmeg Substances 0.000 description 1
• 239000007764 o/w emulsion Substances 0.000 description 1
• 229960001905 ocriplasmin Drugs 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
• JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 206010030306 omphalitis Diseases 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 208000005963 oophoritis Diseases 0.000 description 1
• 239000002997 ophthalmic solution Substances 0.000 description 1
• 229940054534 ophthalmic solution Drugs 0.000 description 1
• 229940037982 ophthalmologicals Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
• 229950006354 orantinib Drugs 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
• 201000011029 ovarian embryonal carcinoma Diseases 0.000 description 1
• 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
• SIWVEOZUMHYXCS-UHFFFAOYSA-N oxo(oxoyttriooxy)yttrium Chemical compound O=[Y]O[Y]=O SIWVEOZUMHYXCS-UHFFFAOYSA-N 0.000 description 1
• GIPDEPRRXIBGNF-KTKRTIGZSA-N oxolan-2-ylmethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC1CCCO1 GIPDEPRRXIBGNF-KTKRTIGZSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• MZRDSGWDVDESRC-VNWQTDIGSA-L padeliporfin Chemical compound [Pd+2].[N-]1C(C=C2[C@H]([C@H](CCC(O)=O)C(=N2)C(CC(=O)OC)=C2C(=C(C)C(=C3)[N-]2)C(=O)NCCS(O)(=O)=O)C)=C(C)C(C(C)=O)=C1C=C1[C@H](C)[C@@H](CC)C3=N1 MZRDSGWDVDESRC-VNWQTDIGSA-L 0.000 description 1
• 229950004431 padeliporfin Drugs 0.000 description 1
• 108010049593 padeliporfin Proteins 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 201000007407 panuveitis Diseases 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 229960005492 pazopanib hydrochloride Drugs 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 229960003407 pegaptanib Drugs 0.000 description 1
• 229940005014 pegaptanib sodium Drugs 0.000 description 1
• 229950004427 pegdinetanib Drugs 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 150000002960 penicillins Chemical class 0.000 description 1
• FWZLYKYJQSQEPN-SKLAJPBESA-N peregrine Chemical compound OC1[C@H]2[C@@H]3C4([C@@H]5C6OC(C)=O)C(OC)CC[C@@]5(C)CN(CC)[C@H]4C6[C@@]2(OC)C[C@H](OC)[C@H]1C3 FWZLYKYJQSQEPN-SKLAJPBESA-N 0.000 description 1
• FWZLYKYJQSQEPN-UHFFFAOYSA-N peregrine Natural products OC1C2C3C4(C5C6OC(C)=O)C(OC)CCC5(C)CN(CC)C4C6C2(OC)CC(OC)C1C3 FWZLYKYJQSQEPN-UHFFFAOYSA-N 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 210000003668 pericyte Anatomy 0.000 description 1
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
• 230000005043 peripheral vision Effects 0.000 description 1
• 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• 229960005323 phenoxyethanol Drugs 0.000 description 1
• PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• 150000003009 phosphonic acids Chemical class 0.000 description 1
• MCTOGTBIQBEIBZ-QHWUVJKOSA-K photrex Chemical compound CCOC(=O)C([C@@]1([C@H]2C)CC)=CC3=C1N([Sn](N14)(Cl)Cl)C2=CC(C(=C2C)CC)=NC2=CC1=C(CC)C(C)=C4C=C1C(CC)=C(C)C3=N1 MCTOGTBIQBEIBZ-QHWUVJKOSA-K 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 235000002949 phytic acid Nutrition 0.000 description 1
• 239000000467 phytic acid Substances 0.000 description 1
• 229940068041 phytic acid Drugs 0.000 description 1
• 238000013310 pig model Methods 0.000 description 1
• 229960001416 pilocarpine Drugs 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
• 208000008423 pleurisy Diseases 0.000 description 1
• 206010035653 pneumoconiosis Diseases 0.000 description 1
• 229920001992 poloxamer 407 Polymers 0.000 description 1
• 229940044476 poloxamer 407 Drugs 0.000 description 1
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
• 229940065514 poly(lactide) Drugs 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 239000004584 polyacrylic acid Substances 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 238000012667 polymer degradation Methods 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
• 235000010235 potassium benzoate Nutrition 0.000 description 1
• 239000004300 potassium benzoate Substances 0.000 description 1
• 229940103091 potassium benzoate Drugs 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
• 239000004224 potassium gluconate Substances 0.000 description 1
• 235000013926 potassium gluconate Nutrition 0.000 description 1
• 229960003189 potassium gluconate Drugs 0.000 description 1
• 229940096992 potassium oleate Drugs 0.000 description 1
• 229940093916 potassium phosphate Drugs 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
• 235000019252 potassium sulphite Nutrition 0.000 description 1
• MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
• 229920003124 powdered cellulose Polymers 0.000 description 1
• 235000019814 powdered cellulose Nutrition 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229940063162 pred mild Drugs 0.000 description 1
• 229960002800 prednisolone acetate Drugs 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 1
• 229950003608 prinomastat Drugs 0.000 description 1
• YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
• 230000001023 pro-angiogenic effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 229940095574 propionic acid Drugs 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229940093625 propylene glycol monostearate Drugs 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 235000020236 pumpkin seed Nutrition 0.000 description 1
• 210000004915 pus Anatomy 0.000 description 1
• YBBJKCMMCRQZMA-UHFFFAOYSA-N pyrithione Chemical compound ON1C=CC=CC1=S YBBJKCMMCRQZMA-UHFFFAOYSA-N 0.000 description 1
• 229960002026 pyrithione Drugs 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 150000007660 quinolones Chemical class 0.000 description 1
• 229960002633 ramucirumab Drugs 0.000 description 1
• 229920005604 random copolymer Polymers 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 229950007043 rebastinib Drugs 0.000 description 1
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 229960004836 regorafenib Drugs 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 210000003994 retinal ganglion cell Anatomy 0.000 description 1
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
• 230000004250 retinal swelling Effects 0.000 description 1
• 210000001210 retinal vessel Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 229960003292 rifamycin Drugs 0.000 description 1
• HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
• CEFJVGZHQAGLHS-UHFFFAOYSA-N ripretinib Chemical compound O=C1N(CC)C2=CC(NC)=NC=C2C=C1C(C(=CC=1F)Br)=CC=1NC(=O)NC1=CC=CC=C1 CEFJVGZHQAGLHS-UHFFFAOYSA-N 0.000 description 1
• 108700002400 risuteganib Proteins 0.000 description 1
• 229960003522 roquinimex Drugs 0.000 description 1
• MCTOGTBIQBEIBZ-RHJKTMSGSA-K rostaporfin Chemical compound CCOC(=O)C([C@]1([C@H]2C)CC)=CC3=C1N([Sn](N14)(Cl)Cl)C2=CC(C(=C2C)CC)=NC2=CC1=C(CC)C(C)=C4C=C1C(CC)=C(C)C3=N1 MCTOGTBIQBEIBZ-RHJKTMSGSA-K 0.000 description 1
• 229950005932 rostaporfin Drugs 0.000 description 1
• 108091008601 sVEGFR Proteins 0.000 description 1
• 229940085605 saccharin sodium Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 238000004626 scanning electron microscopy Methods 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 210000004706 scrotum Anatomy 0.000 description 1
• 208000014956 scrotum Paget disease Diseases 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 201000003385 seborrheic keratosis Diseases 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 201000005574 senile angioma Diseases 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 201000003772 severe nonproliferative diabetic retinopathy Diseases 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 229940057910 shea butter Drugs 0.000 description 1
• 150000004756 silanes Chemical class 0.000 description 1
• HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
• 229910010271 silicon carbide Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
• 229910052814 silicon oxide Inorganic materials 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
• 229940071536 silver acetate Drugs 0.000 description 1
• 229940071575 silver citrate Drugs 0.000 description 1
• CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 1
• 239000002356 single layer Substances 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000005549 size reduction Methods 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000000195 skin tag Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010378 sodium ascorbate Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
• 229960005055 sodium ascorbate Drugs 0.000 description 1
• 229960003885 sodium benzoate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
• APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
• 229940037001 sodium edetate Drugs 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 229940045872 sodium percarbonate Drugs 0.000 description 1
• JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
• 235000010334 sodium propionate Nutrition 0.000 description 1
• 239000004324 sodium propionate Substances 0.000 description 1
• 229960003212 sodium propionate Drugs 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 229940001482 sodium sulfite Drugs 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
• 239000001570 sorbitan monopalmitate Substances 0.000 description 1
• 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
• 239000001589 sorbitan tristearate Substances 0.000 description 1
• 229960004129 sorbitan tristearate Drugs 0.000 description 1
• 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 229950001248 squalamine Drugs 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 238000011146 sterile filtration Methods 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 229960002812 sunitinib malate Drugs 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
• 229960005314 suramin Drugs 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229950001899 tasquinimod Drugs 0.000 description 1
• ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 description 1
• 239000006068 taste-masking agent Substances 0.000 description 1
• 230000004488 tear evaporation Effects 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 229950003046 tesevatinib Drugs 0.000 description 1
• HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 206010062123 testicular embryonal carcinoma Diseases 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 229940072958 tetrahydrofurfuryl oleate Drugs 0.000 description 1
• CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 description 1
• 229940034915 thalomid Drugs 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 229960004605 timolol Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 239000010936 titanium Substances 0.000 description 1
• 229910052719 titanium Inorganic materials 0.000 description 1
• 229960000940 tivozanib Drugs 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 229940042585 tocopherol acetate Drugs 0.000 description 1
• 239000008181 tonicity modifier Substances 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229940019127 toradol Drugs 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 208000002419 toxicodendron dermatitis Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 238000004627 transmission electron microscopy Methods 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 229940113006 travatan Drugs 0.000 description 1
• 229960002368 travoprost Drugs 0.000 description 1
• 229960002117 triamcinolone acetonide Drugs 0.000 description 1
• 235000013337 tricalcium citrate Nutrition 0.000 description 1
• 235000019731 tricalcium phosphate Nutrition 0.000 description 1
• LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
• 229940038017 triesence Drugs 0.000 description 1
• 229940117013 triethanolamine oleate Drugs 0.000 description 1
• 229960001082 trimethoprim Drugs 0.000 description 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
• VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
• 150000004961 triphenylmethanes Chemical class 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 1
• 229960005066 trisodium edetate Drugs 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 229940094060 tykerb Drugs 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 229950008081 unoprostone isopropyl Drugs 0.000 description 1
• 208000000143 urethritis Diseases 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 108010060757 vasostatin Proteins 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
• 239000010679 vetiver oil Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 229940061392 visudyne Drugs 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 239000000341 volatile oil Substances 0.000 description 1
• 229950001212 volociximab Drugs 0.000 description 1
• 229940069559 votrient Drugs 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 208000028010 vulval Paget disease Diseases 0.000 description 1
• 208000002003 vulvitis Diseases 0.000 description 1
• 208000010484 vulvovaginitis Diseases 0.000 description 1
• 239000007762 w/o emulsion Substances 0.000 description 1
• 235000020234 walnut Nutrition 0.000 description 1
• 239000008170 walnut oil Substances 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000010497 wheat germ oil Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 229940002639 xalatan Drugs 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 208000005494 xerophthalmia Diseases 0.000 description 1
• 229940043810 zinc pyrithione Drugs 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
• PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
• 229910001928 zirconium oxide Inorganic materials 0.000 description 1
• GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
• 229940043785 zortress Drugs 0.000 description 1
• 229940065583 zylet Drugs 0.000 description 1
• 235000004835 α-tocopherol Nutrition 0.000 description 1
• 239000002076 α-tocopherol Substances 0.000 description 1
• OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1